Objective: Advanced biliary tree cancers are often diagnosed at an advanced or metastatic stage and have poor prognoses. We reported the promising anti-tumor activity of gemcitabine/5-fluorouracil (5-FU)/cisplatin (CDDP) therapy, called 'GFP chemotherapy' in a pilot study. Methods: Twenty-one patients with advanced or metastatic biliary tree cancers with no prior chemotherapy were enrolled in this Phase II trial. Patients were treated on 4-week cycle GFP chemotherapy consisting of gemcitabine at 1000 mg/m 2 on days 1, 8 and 15, and 5-FU at 150 mg/m 2 and CDDP at 3 mg/m 2 on days 1 -5, 8 -12 and 15 -19. After two cycles, a 4-week outpatient treatment of gemcitabine (1000 mg/m 2 ) on days 1 and 15 combined with 5-FU (500 mg/m 2 ) and CDDP (7 mg/m 2 ) on days 1 and 15 was commenced. Treatment was repeated until tumor progression or remission allowing curative operation, or unacceptable toxicity occurred. Results: Of these 21 patients, no complete responses were observed, but 7 patients (33.3%) demonstrated partial responses (PRs) with an additional 12 patients (57.2%) having stable diseases, as assessed by RECIST. Three patients with PRs were treated by curative operation after GFP chemotherapy, and all of them survived with no recurrence for over 3 years. The median overall survival time was 18.8 months, and median time to progression was 13.4 months. Grade 3 side effects such as leukopenia, thrombocytopenia and anemia were found in six patients (28.6%), but no patients dropped out because of toxicity. Conclusions: This GFP chemotherapy has promising anti-tumor activity and is well tolerated in patients with advanced biliary tree cancers.
INTRODUCTION
Biliary tree cancer is a relatively rare tumor and is often diagnosed at an advanced or metastatic stage with a rather grim, 1-year survival rate of only 25% (1, 2) . Although surgery remains the only curative treatment for patients with biliary tree cancers, most patients are candidates for palliative chemotherapy at initial presentation (1, 3) .
Gemcitabine (2 0 ,2 0 -difluorodeoxycytidine), a deoxycytidine analogue, has broad activity in a variety of solid tumors, including biliary tree cancers. Objective response rates up to $30%, abrogation of 93% of progressive disease and overall survival (OS) times ranging from 6.3 to 16 months have been reported (4) . Therefore, gemcitabine may be the key drug for establishing the standard of chemotherapy in patients with advanced biliary tree cancers. In recent Phase II trials, it was shown that the addition of cisplatin (CDDP), oxaliplatin or capecitabine may increase the chemotherapeutic effects (5 -9) . According to a pooled analysis of 112 Phase II clinical trials, the combination of gemcitabine with platinum compounds represents the provisional standard of chemotherapy for advanced biliary tree cancers, unless a new evidenced-based standard can be defined (10) .
We previously reported the promising anti-tumor activity and good patient tolerance of gemcitabine/5-fluorouracil (5-FU)/CDDP called 'GFP chemotherapy' for patients with advanced biliary tree cancers in a pilot study (11) . Of eight patients in a pilot study, three patients (37.5%) demonstrated partial response (PR) with an three patients (37.5%) having stable disease (SD) (11) . Grade 3/4 side effects, such as leucopenia, thrombocytopenia and anemia, were found in four patients (50%), but no patients dropped out because of toxicity (11) . Here, we further evaluate the efficacy and toxicity of GFP chemotherapy for advanced biliary tree cancer in a Phase II trial comprising 21 patients.
PATIENTS AND METHODS

ELIGIBILITY
Patients were eligible if they were over 20 years and had pathologically proven, measurable and unresectable locally advanced or metastatic adenocarcinoma arising from intrahepatic and extrahepatic biliary ducts or the gallbladder. No prior chemotherapy was allowed. Additional inclusion criteria included Eastern Cooperative Oncology Group (ECOG) performance status 2 and adequate organ function (neutrophils .1.5 Â 10 3 /ml, platelets .1.0 Â 10 5 /ml, serum creatinine ,160 mmol/l or actual or calculated creatinine clearance .60 ml/min, alanine transaminase ,5Â upper limit of normal (ULN) and total bilirubin ,3Â ULN and stable for 2 weeks). Written informed consent was obtained from each patient, and the protocol of this Phase II trial was approved by the ethics committee of the hospital.
TREATMENT
Patients were treated on a 4-week cycle on first 2 months as inpatient or outpatient (Fig. 1A) . Gemcitabine 1000 mg/m 
ASSESSMENT AND STATISTICS
The primary endpoint was response rate and the secondary endpoint was toxicity evaluation. A sample size of 19 was required to accept the hypothesis that the true response rate was .15% with 90% power and to reject the hypothesis that the response rate was ,5% significance. Assuming that 5 -10% patients were inassessable, 21 patients were planned to be accrued for this Phase II trial. Tumor response was assessed using Response Evaluation Criteria in Solid tumors (RECIST) (11) , with computer tomography scans at baseline and every two cycles or 8 weeks of treatment. Responses were confirmed by computed tomography at least 4 weeks later. Continuous variables were expressed as means + SE. The survival curves were generated by the Kaplan -Meier method. The primary endpoint of interest was the overall response rate, with the secondary endpoints including OS, time to progression (TTP) and safety and tolerability of the treatment.
RESULTS
PATIENTS' CHARACTERISTICS
Between April 2005 and March 2008, 21 patients were enrolled in this trial. No patient was removed from this study for severe toxicity. Patients' characteristics are summarized in Table 1 . Eight patients (38.1%) had intrahepatic cholangiocarcinoma, seven patients (33.3%) had gallbladder carcinoma and six patients (28.6%) had extrahepatic cholangiocarcinoma. Twelve patients (57.1%) had distant metastasis in the liver, lung or distant lymph nodes, and nine patients (42.9%) were locally advanced; all were judged as inoperable cases.
RESPONSE AND SURVIVAL
Responses of all 21 patients to GFP chemotherapy are summarized in Fig. 2A . No complete responses were noted. Seven patients (33.3%) achieved PRs; therefore, the overall response rate was 33.3%. In addition, 12 patients (57.2%) had SD (57.2%); therefore, the disease control rate was 90.5%. Two patients (9.5%) had progress of the disease, and both of these died within 6 months. Three patients (14.3%) who had locally advanced gallbladder carcinoma underwent an additional curative operation after two cycles of inpatient GFP chemotherapy. Two patients were suspected of having duodenal invasion, but tumor remission of over 50% caused a release from duodenal stenosis after GFP chemotherapy. The other patient was suspected of having peritoneal dissemination because of slight ascites at the Winslow foramen and the thickness of the omentum, but these symptoms disappeared after GFP chemotherapy. All three patients have survived for .3 years.
The survival curves of all 21 patients generated by the Kaplan -Meier method is shown in Fig. 2B . The 1-year survival rate was 57.5%. The median TTP was 13.4 months, and the median survival time was 18.8 months. Three patients (37.5%) undergoing curative operation after GFP chemotherapy have been alive without tumor recurrence beyond 36 months.
TOXICITIES
Toxicities were evaluable in all patients and are summarized in Table 2 . Hematologic toxicity was significant; Grade 3/4 leukopenia developed in six patients (28.6%), anemia in two patients (9.5%) and thrombocytopenia in three patients (14.3%). Grade 2 appetite loss developed in three patients (14.3%), but Grade 3/4 non-hematological toxicities such as nausea, vomiting, appetite loss or diarrhea were found. Seven patients (33.3%) required dose reductions of gemcitabine to 800 mg/m 2 or a temporary discontinuation of chemotherapy because of toxicities.
DISCUSSION
The overall response rate was 33.3%, additional 57.2% showed disease stabilization and an acceptable toxicity profile was gained in our Phase II trial of GFP chemotherapy for patients with advanced biliary tree cancers. The median TTP and OS were 13.4 and 18.8 months, respectively. These results are comparable to impressive responses in our previous pilot study of GFP chemotherapy (11) . According to the 'Guidelines for chemotherapy of biliary tract and ampullary carcinomas' published by the Japanese Society of Hepato-biliary Pancreatic Surgery and Japan Society of Clinical Oncology (12), gemcitabine or tegafur/gimeracil/ oteracil potassium (S-1) are recommended as first-line chemotherapy for unresectable advanced biliary tree cancers. Our results are some of the best results obtained so far in the management of advanced biliary tree cancers, including those of the various recent Phase II trials including gemcitabine and S-1 summarized in Table 3 (5 -7,13-21). The combination of gemcitabine, 5-FU and CDDP has been considered synergistic based on laboratory data. It has been shown that gemcitabine may increase the formation of DNA -platinum adducts, and CDDP may increase the incorporation of gemcitabine into DNA. It has been shown that this synergistic interaction is related to a decrease in the repair of DNA -platinum adducts (22, 23) . According to the pooled analysis of 112 Phase II clinical trials, gemcitabine combined with platinum compounds represents the provisional standard of chemotherapy in advanced biliary tree cancers (10) . In addition, at annual meeting of American Society of Clinical Oncology (ASCO) 2009, Valle et al. (24) reported that gemcitabine and CDDP combination chemotherapy significantly improved the OS of patients with advanced biliary tract cancer in British Phase III trial. On the other hand, some evidence supports the combination of gemcitabine with 5-FU (25, 26) . By its direct inhibition of ribonucleotide reductase, gemcitabine potentially augments the activity of 5-FU. Administered with 5-FU, it should delay further deoxyuridine monophosphate (dUMP) production, potentiating and prolonging the inhibition by 5dUMP. In recent meta-analysis of chemotherapy for locally advanced and metastatic pancreas cancers, there were significant survival benefits of gemcitabine-based combinations over gemcitabine alone (27, 28) . In addition, as mentioned in Figure 2 . Responses of all 21 patients to GFP chemotherapy are summarized (A). No complete responses (CRs) were noted. Seven patients (33.3%) achieved partial responses (PRs); therefore, the overall response rate was 33.3%. In addition, 12 patients (57.2%) had stable disease for a disease control rate of 90.5%. The survival curves of all 21 patients generated by the Kaplan-Meier method are shown (B). The 1-year survival rate was 57.5%. SD, stable disease; PD, progressive disease; RR, response rate; DCR, disease control rate. Table 3 . Summary of recent trials of Phase II study in biliary tree cancers our pilot study, the synergism should be schedule-dependent (11, 26, 29) . The order of administration in three agents should be gemcitabine, CDDP and 5-FU. Grade 3/4 hematologic toxicity was found in six patients (28.6%) and Grade 2 appetite loss was found in three patients (14.3%). In a recent Phase II study of single-agent gemcitabine in 40 patients with advanced biliary tree cancers, Grade 3/4 hematologic toxicity was found in 12 patients (30.0%) (13) . In addition, compared with the adverse effects reported in recent Phase II trials of chemotherapy in patients with advanced biliary tree cancers (5 -7,13 -21), overall this chemotherapy was relatively well tolerated.
In conclusion, our Phase II trial indicates that this regimen of gemcitabine combined with 5-FU and CDDP is an active and a well-tolerated new therapeutic option as chemotherapy for patients with advanced biliary tree cancer. However, it should be further investigated whether GFP chemotherapy confers survival benefits when compared with gemcitabine alone.
